Imiglucerase
CEREZYME
- Dosage form
- Tablet
- Available strengths
- 400 Units/vial
- Drug class
- Enzyme replacement therapy (recombinant glucocerebrosidase)
- Common brand
- CEREZYME
Clinical overview. Imiglucerase (Cerezyme) is a recombinant enzyme replacement therapy given by intravenous infusion, usually every 2 weeks, to treat the non-neurological manifestations of type 1 and type 3 Gaucher disease. Dosing is individualized and titrated to each patient's response, ranging from 2.5 to 60 units per kilogram per infusion. The most serious risk is hypersensitivity, including anaphylaxis, which can occur during or after an infusion, so treatment is given under medical supervision with appropriate monitoring.
Indication
Common therapeutic uses
- Imiglucerase is used as long-term enzyme replacement therapy for confirmed type 1 (non-neuronopathic) Gaucher disease.
- It is also used for the non-neurological manifestations of type 3 (chronic neuronopathic) Gaucher disease, including anemia, low platelet counts, bone disease, and an enlarged liver or spleen.
- Imiglucerase has not been shown to improve the neurological symptoms of type 3 Gaucher disease.
Pregnancy
Risk assessment and monitoring considerations
- No studies have been conducted in pregnant women, and it is unknown whether imiglucerase crosses the placenta or affects fertility.
- Untreated or undertreated Gaucher disease can worsen during pregnancy, with increased organ enlargement, worsening anemia or low platelets, bleeding, bone crises, and bone tissue death.
- Imiglucerase may be continued or started during pregnancy after an individualized risk-benefit assessment, with close monitoring throughout for pregnancy-related complications of Gaucher disease.
Breastfeeding
Infant exposure considerations
- It is not known whether imiglucerase passes into human breast milk.
- Caution should be used when imiglucerase is given to a breastfeeding woman, since many drugs are excreted in human milk.
Geriatrics
Dosing and tolerability considerations
- No data are available for patients 65 years of age and older, so Health Canada has not authorized a distinct geriatric indication; treatment should be individualized and monitored closely in this age group.
Pediatrics
Use in children and adolescents
- Imiglucerase is authorized for patients 2 to 16 years of age, based on established safety and efficacy data.
- It is not authorized for children under 2 years of age, since no data are available to Health Canada.
Dosage & Administration
Practical dosing and administration
- Dosing is individualized; treatment is usually started at 2.5 units per kilogram of body weight given 3 times weekly, up to 60 units per kilogram given as infrequently as once every 2 weeks, and titrated based on clinical response.
- Higher doses, up to 120 units per kilogram every 2 weeks, have been used safely in patients with type 3 Gaucher disease.
- The lyophilized powder must be reconstituted with sterile water for injection to a concentration of 40 units per mL, then further diluted with 0.9% sodium chloride to a final volume of 100 to 200 mL before use.
- Imiglucerase is given by intravenous infusion over 1 to 2 hours, at a maximum infusion rate of 1 unit per kilogram per minute, optionally through a low-protein-binding in-line filter.
- Each vial is for single use only, and any unused portion must be discarded, since the product contains no preservatives.
- If a dose is missed, contact your doctor promptly, since keeping the total monthly dose consistent is important to prevent the underlying disease from progressing.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Doses up to 240 U/kg given every two weeks have been reported in clinical experience without obvious toxicity.
- In the event of overdose, the infusion should be stopped immediately.
- The patient should be closely monitored in a hospital setting for infusion-related reactions.
Common side effects
Frequently reported tolerability concerns
- Headache may occur.
- Dizziness may occur.
- Flushing may occur.
- A fast heartbeat (tachycardia) may occur.
- Shortness of breath (dyspnea) may occur.
- Cough may occur.
- Nausea may occur.
- Vomiting may occur.
- Abdominal cramping may occur.
- Diarrhea may occur.
- Skin rash may occur.
- Hives (urticaria) or swelling (angioedema) may occur.
- Itching (pruritus) may occur.
- Fatigue may occur.
- Fever may occur.
- Chills may occur.
- Back pain may occur.
- Infusion-site reactions, such as discomfort, burning, redness, or swelling, may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe hypersensitivity reactions, including anaphylaxis, can occur during or shortly after an infusion.
- Pulmonary hypertension has been reported in patients receiving imiglucerase, though it is also a known complication of untreated Gaucher disease and no causal link with the drug has been established.
- Antibodies against imiglucerase develop in some patients, usually within the first year of treatment, and increase the risk of hypersensitivity and infusion reactions.
- A sterile abscess at the infusion site has been reported.
- Transient swelling of the limbs (peripheral edema) has been reported rarely.
- Chest discomfort and a bluish skin discoloration (cyanosis) associated with infusion reactions have been reported.
- Seek urgent medical attention for signs of a severe allergic reaction, such as swelling of the face or throat, difficulty breathing, or chest tightness, during or after an infusion.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with a history of hypersensitivity reactions to imiglucerase, considering pre-medication with antihistamines and/or corticosteroids and a slower infusion rate.
- Use with caution in patients previously treated with alglucerase, a placental-derived enzyme product, who developed antibodies or hypersensitivity, since cross-reactivity may occur.
- Use with caution and monitor closely when re-administering imiglucerase after a severe hypersensitivity reaction, weighing the risks and benefits for the individual patient.
- Use with caution in patients with respiratory symptoms, evaluating for pulmonary hypertension.
- Periodic monitoring for antibody formation is recommended during the first year of therapy and again around 18 months.
- Cardiopulmonary resuscitation equipment and appropriate medical support should be available during infusions, particularly early in treatment.
- Use with caution in pregnant patients with Gaucher disease, given that the disease itself can worsen during pregnancy; individualized risk-benefit assessment and close monitoring are required.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with severe hypersensitivity to imiglucerase or to any ingredient in the formulation or component of the container.
Drug interactions
Clinically relevant combinations
- Formal drug-drug interaction studies have not been conducted with imiglucerase.
- Interactions with herbal products have not been established.
- Pre-treatment with antihistamines and/or corticosteroids is commonly used to reduce the risk of infusion-related hypersensitivity reactions; this is a supportive measure rather than a true pharmacologic interaction.
Food interactions
Meal-related administration
- No food interactions have been established for this intravenous enzyme replacement therapy.
Time of administration
Practical scheduling
- Imiglucerase is given by intravenous infusion in a clinic or home-care setting, typically once every 2 weeks or on an individualized schedule, rather than tied to a specific time of day.
- Regular, on-schedule infusions are important, since delaying doses allows the underlying enzyme deficiency to worsen; contact your doctor promptly if a dose is missed.
Storage
Product handling
- Store unopened lyophilized vials refrigerated at 2°C to 8°C; do not use past the expiry date on the label.
- Unopened vials may be kept at room temperature, 23°C to 27°C, for up to 48 hours if refrigeration is unavailable.
- After reconstitution with sterile water, use within 12 hours if kept refrigerated or at room temperature; after dilution with saline, use within 24 hours if kept refrigerated or at room temperature.
- Imiglucerase contains no preservatives, so reconstituted and diluted solutions must be prepared immediately before use, and any unused portion discarded.
Patient take-away
Key counselling points for a quick closing summary
- Imiglucerase (Cerezyme) is a lifelong intravenous enzyme replacement therapy for type 1 or type 3 Gaucher disease, usually given every 2 weeks in a clinic or at home by a trained healthcare professional.
- Most side effects are mild and infusion-related, such as headache, flushing, nausea, or itching, and often improve by slowing the infusion rate.
- Seek immediate medical attention for signs of a severe allergic reaction, especially during or shortly after an infusion.
- Keep infusions on a regular schedule, since interrupting therapy can allow the disease to progress; contact your doctor if a dose is missed rather than skipping it.
- Regular blood tests and organ monitoring are needed to track your response to treatment over time.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.